Sign up for free to view insider transactions by individual.
XORTX Completes Manufacturing of Clinical Drug Supply
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
XORTX Therapeutics Starts Production Of Drug, Tablet Manufacturing For Its XRx-026 Trial To Treat Gout
XORTX Re-Engages Investor Relations Program
XORTX Announces Termination and Postponement of Investor Relations Program
XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency
XORTX Announces Director Resignation
XORTX Appoints New Director
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
XORTX Therapeutics Appoints Mika Grasso Co-CEO
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
XORTX Announces Closing of US$5 Million Public Offering
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.